Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%

• Turn Therapeutics reported newly published, peer-reviewed preclinical results for GX-03 in a mouse model of dermatitis-like inflammation.
• Findings were already presented via publication in Life, not flagged for a future medical meeting.
• GX-03 pretreatment reduced inflammatory signaling tied to skin inflammation and itch, producing a selective effect rather than broad immune suppression.
• Animals receiving GX-03 developed materially less severe dermatitis than untreated controls, supporting a prevention-oriented positioning in inflammatory skin disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260820905760) on August 20, 2026, and is solely responsible for the information contained therein.